← All trials
NCT05311254
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2022
- Primary completion
- Mar 14, 2023
- Completion date
- Mar 14, 2023
- First posted
- Apr 5, 2022
- Last posted
- Apr 5, 2022
- Enrollment
- 156
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hospital Universitario Central de AsturiasLead sponsor
- Hospital Universitario Central de AsturiasReponsible party - principal investigator
- University of CantabriaCollaborator
- Universidad Carlos III MadridCollaborator
- Hospital Universitario Central de AsturiasSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.